The client required an invalidity assessment of a patented intragastric volume-occupying device designed to support minimally invasive obesity treatment. The central question was whether earlier technical disclosures could undermine the patentability of the claimed combination of delivery, inflation, sealing and controlled deflation features.
Unlike a conventional gastric balloon, which is generally introduced through an endoscopic or catheter-based procedure, the subject invention described a swallowable system designed to deliver a compact volume-occupying component into the stomach. The delivery capsule was intended to degrade after ingestion, allowing the device to deploy and perform its intended function.
